Metamark Genetics Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Metamark Genetics is a privately held biotechnology company focused on improving cancer care through diagnostic and prognostic testing, with an emphasis on clinical proteomics—the study of protein signatures in healthy and diseased cells. Founded in 2007 and based in Cambridge, Massachusetts, the firm operates with a small, specialized team and is positioned within the broader fields of cancer biology and personalized medicine. It pursues diagnostics and management strategies for urologic cancers, particularly prostate and bladder cancers. Its primary offering, ProMark, is a protein-based biopsy test designed to improve prognostic accuracy for men diagnosed with prostate cancer and to inform treatment choices. Metamark announced the nationwide availability of ProMark in 2014, and a study published in The Oncologist in 2015 indicated that using ProMark for early-stage disease could support more cost-effective care compared with risk classification guidelines alone.